U.S. growth for prescription drug sales is expected to slow to 1-2%. That's why Big Pharma firms (JNJ, PFE, MRK, WYE) are turning to emerging markets, where sales of Western prescription drugs are expected to grow by up to 15% a year to as much as $161B.